Scarica l'app Stockscreener
71.10
2.37%
-1.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$72.96
Aprire:
$71.02
Volume 24 ore:
70,082
Relative Volume:
0.07
Capitalizzazione di mercato:
$2.04B
Reddito:
$55.23M
Utile/perdita netta:
$-164.08M
Rapporto P/E:
-10.39
EPS:
-6.8461
Flusso di cassa netto:
$-208.68M
1 W Prestazione:
-4.82%
1M Prestazione:
+8.09%
6M Prestazione:
+21.76%
1 anno Prestazione:
+8,786%
Intervallo 1D:
$70.93
$71.23
Intervallo di 1 settimana:
$70.67
$77.97
Portata 52W:
$0.432
$77.97
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
71.08 | 2.07B | 55.23M | -164.08M | -208.68M | -6.8461 |
VRTX
Vertex Pharmaceuticals Inc
|
452.50 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.13 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.41 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.84 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | TD Cowen | Buy |
| 2026-02-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
What Nektar Therapeutics (NKTR)'s AAD 2026 REZPEG Phase 2b Spotlight Means For Shareholders - simplywall.st
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph
Nektar Therapeutics stock hits 52-week high at 77.36 USD - Investing.com
Nektar Therapeutics stock hits 52-week high at 77.36 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighHere's Why - MarketBeat
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com
Wedbush initiates coverage of Nektar Therapeutics (NKTR) with neutral recommendation - MSN
Wedbush Initiates Coverage on Nektar Therapeutics (NKTR) with Ne - GuruFocus
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Wedbush - MarketBeat
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Wedbush initiates Nektar Therapeutics stock with neutral rating By Investing.com - Investing.com Australia
Wedbush initiates Nektar Therapeutics stock with neutral rating - Investing.com
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead - GlobeNewswire
Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target - marketscreener.com
Wedbush Starts Nektar Therapeutics (NKTR) at Neutral - StreetInsider
Nektar Therapeutics Faces High-Stakes AAD Data Test as Sky-High Valuation Leaves Little Room for Error - Bitget
A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting - simplywall.st
Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Nektar Therapeutics stock is trending Tuesday: What's going on? - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
Apogee strengthens case for longer-lasting eczema drug - BioPharma Dive
Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections - statnews.com
NKTR Traders Confront Legal Binary Deadline Against Forthcoming Clinical Milestone at AAD 2026 - Bitget
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
2 Healthcare Stocks to Buy Before They Get Bought Out - AOL.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
Nektar rises after mid-stage trial data for lead asset in hair loss disorder - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The AI Journal
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm - WFXG
Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting - Finviz
Two skin and hair-loss studies from Nektar get oral AAD slots - Stock Titan
NKTR Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Abivax & Nektar Therapeutics: Clinical-Stage Biotech Drug Development in 2026News and Statistics - IndexBox
2 Healthcare Shares to Consider Purchasing Before Potential Buyouts - Bitget
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nektar Therapeutics Azioni (NKTR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer |
Feb 18 '26 |
Sale |
73.00 |
180 |
13,140 |
21,174 |
| ROBIN HOWARD W | President & CEO |
Feb 18 '26 |
Sale |
73.00 |
423 |
30,879 |
75,489 |
0.19%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):